Insmed Incorporated develops and commercializes biopharmaceutical therapies for serious diseases, with a commercial respiratory portfolio that includes ARIKAYCE® (amikacin liposome inhalation suspension) and BRINSUPRI® (brensocatib). Its pipeline spans pulmonary, inflammatory, immunology and rare-disease programs, including TPIP and INS1148, alongside early research in gene therapy, AI-driven protein engineering, protein manufacturing, RNA end-joining and synthetic rescue.
Recurring company news covers product revenue trends, regulatory authorizations and label-development activity for ARIKAYCE and BRINSUPRI, clinical data in MAC lung disease, non-cystic fibrosis bronchiectasis and inflammatory conditions, and presentations at medical and investor conferences. Updates also include portfolio-prioritization decisions, financial results, employee equity inducement grants and other governance-related announcements.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Insmed Incorporated (Nasdaq: INSM), a biopharmaceutical company dedicated to treating serious rare diseases, will host an investor and analyst event titled "The Future of Rare at Insmed" on May 8, 2023, from 8:00 a.m. to 12:00 p.m. ET in New York. The event will focus on Insmed's early-stage research programs and feature presentations from management and research leaders discussing their innovative platforms. The company aims to develop at least six new investigational new drug applications by 2025. A live webcast will be available on their website, with a replay accessible 30 minutes after the event's conclusion. Insmed's mission includes advancing therapies targeting unaddressed medical needs in rare pulmonary disorders and other serious conditions.
Insmed Incorporated (Nasdaq: INSM) announced it will release its first quarter 2023 financial results on May 4, 2023. A conference call for investors will be held at 8:30 a.m. ET on the same day to discuss the results and provide a business update.
Participants can join the call by dialing (833) 470-1428 for U.S. calls or (929) 526-1599 for international calls, using access code 468531. The call will also be available via a live webcast on Insmed's website.
A replay will be accessible after the call, lasting until June 3, 2023. Insmed is dedicated to treating serious and rare diseases with its approved therapies and an expanding pipeline.